Education
About Us
Working with TipRanks
Follow Us
Veracyte (VCYT)
NASDAQ:VCYT
VCYT Stock Chart & Stats
$35.77
$0.68(1.60%)
At close: 4:00 PM EST
$35.77
$0.68(1.60%)
Day’s Range― - ―
52-Week Range$22.61 - $50.71
Previous CloseN/A
Volume253.49K
Average Volume (3M)819.51K
Market Cap
$2.83B
Enterprise Value$2.55B
Total Cash (Recent Filing)$366.43M
Total Debt (Recent Filing)$40.45M
Price to Earnings (P/E)94.2
Beta1.18
Next Earnings
Feb 25, 2026EPS Estimate
0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.51
Shares Outstanding79,049,170
10 Day Avg. Volume937,824
30 Day Avg. Volume819,506
Financial Highlights & Ratios
PEG Ratio-0.96
Price to Book (P/B)2.58
Price to Sales (P/S)6.79
P/FCF Ratio47.47
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue5.16
Enterprise Value/Gross Profit7.52
Enterprise Value/Ebitda54.17
Forecast
1Y Price Target
$46.25Price Target Upside29.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Core Franchise GrowthAnalyst notes Decipher drove core testing growth with Afirma providing strong support, and testing volumes trending higher across flagship diagnostics, indicating sustained demand for the main products.
Guidance Upside From Planned LaunchesAnalyst points out initial revenue guidance came in above consensus without counting potential contributions from planned test launches, implying upside if those new products achieve commercial traction.
Profitability And Margin ExpansionAnalyst highlights an attractive margin profile and improving operating profitability, expecting adjusted EBITDA margins to rise as gross profit gains are selectively reinvested to fund growth while preserving profitability metrics.
Bears Say
Commercial Adoption And Market Share UncertaintyAnalyst cautions that meaningful valuation upside depends on broad commercial adoption of new tests and the ability to win share from established competitors, outcomes that remain uncertain.
Operational And Integration RisksAnalyst identifies risks from sustaining high growth for core franchises, successful data generation and commercialization of new tests, international expansion challenges and integration with partnered genomics operations, any of which could distract management and affect results.
Pipeline Execution RiskAnalyst warns that ongoing product transitions and multiple pipeline launches introduce uncertainty around near-term timing and execution, which could depress performance if rollouts encounter delays.
Veracyte News
VCYT FAQ
What was Veracyte’s price range in the past 12 months?
Veracyte lowest stock price was $22.61 and its highest was $50.71 in the past 12 months.
What is Veracyte’s market cap?
Veracyte’s market cap is $2.83B.
When is Veracyte’s upcoming earnings report date?
Veracyte’s upcoming earnings report date is Feb 25, 2026 which is in 8 days.
How were Veracyte’s earnings last quarter?
Veracyte released its earnings results on Nov 04, 2025. The company reported $0.51 earnings per share for the quarter, beating the consensus estimate of $0.321 by $0.189.
Is Veracyte overvalued?
According to Wall Street analysts Veracyte’s price is currently Undervalued.
Does Veracyte pay dividends?
Veracyte does not currently pay dividends.
What is Veracyte’s EPS estimate?
Veracyte’s EPS estimate is 0.41.
How many shares outstanding does Veracyte have?
Veracyte has 79,049,170 shares outstanding.
What happened to Veracyte’s price movement after its last earnings report?
Veracyte reported an EPS of $0.51 in its last earnings report, beating expectations of $0.321. Following the earnings report the stock price went up 27.464%.
Which hedge fund is a major shareholder of Veracyte?
Currently, no hedge funds are holding shares in VCYT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Veracyte Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$46.25 (29.30% Upside)
$46.25 (29.30% Upside)
Blogger Sentiment
Bullish
VCYT Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.64%
12-Months-Change
Fundamentals
Return on Equity
2.49%
Trailing 12-Months
Asset Growth
7.28%
Trailing 12-Months
Company Description
Veracyte
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
VCYT Company Deck
VCYT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Veracyte delivered a strong quarter with record revenue growth and profitability, driven by robust performance from its core testing business, particularly Decipher and Afirma. The company achieved a significant milestone by reaching its adjusted EBITDA margin target ahead of schedule. However, challenges remain in the form of declining biopharmaceutical revenue, competitive pressures from new technologies, and a slight decrease in testing ASP.View all VCYT earnings summariesVCYT Stock 12 Month Forecast
Average Price Target
$46.25
▲(29.30% Upside)
Technical Analysis
Travere Therapeutics
―
Celcuity
―
Immunovant
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Ownership Overview
Currently, No data available
---